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Risk factors for lung cancer in COPD – results from the Bergen COPD Cohort Study 
abstract 
 
Background: COPD patients have an increased risk of developing lung cancer, but the 
underlying mechanisms are poorly understood. We aimed to identify risk factors for lung 
cancer in patients from the Bergen COPD Cohort Study. 
Methods: We compared 433 COPD patients with 279 healthy controls, all former or current 
smokers. All COPD patients had FEV1<80% and FEV1/FVC-ratio<0.7. Baseline predictors 
were sex, age, spirometry, body composition, smoking history, emphysema assessed by CT, 
chronic bronchitis, prior exacerbation frequency, Charlson Comorbidity Score, inhalation 
medication and 44 serum/plasma inflammatory biomarkers. Patients were followed up for 9 
years recording incidence of lung cancer. Cox-regression models were fitted for the statistical 
analyses. The biomarkers were evaluated using principal component analysis. 
Results: 28 COPD patients and 3 controls developed lung cancer, COPD patients had a 
significantly higher risk of developing lung cancer, (HR 5.0; 95% CI 1.5-17.1, p<0.01, 
adjusted values). Among COPD patients, emphysema (HR 4.4; 1.7-10.8, p<0.01) and obesity 
(HR 3.3; 1.3-8.5, p=0.02) were associated with a higher cancer rate. Use of inhaled steroids 
was associated with a lower rate (HR 0.4; 0.2-0.9, p=0.03). Smoking status, pack-years 
smoked or levels of systemic inflammatory markers, except for interferon gamma-induced 
protein 10, did not affect the lung cancer rate in patients with COPD. 
Conclusion: Patients with COPD have a higher lung cancer rate compared to healthy controls 
adjusted for smoking. The presence of emphysema and obesity in COPD predicted a higher 
lung cancer risk in COPD patients. Systemic inflammation was not associated with increased 
lung cancer risk. 
 
Risk factors for lung cancer in COPD – results from the Bergen COPD Cohort Study 
Introduction 
COPD and lung cancer are two major causes of morbidity and mortality worldwide. COPD is 
the fourth leading cause of death in the world, whereas lung cancer is the foremost cause of 
cancer deaths 
1
. The incidence of both conditions have been increasing in the last years, and 
this trend is expected to continue for the next decade 
2
. Furthermore, there is a known 
association between these two common disorders 
3
. One obvious explanation for the co-
existence of these conditions is their common risk factors, where tobacco-smoking is the most 
important. However, several studies find that a diagnosis of COPD, regardless of the amount 
of smoking, is an independent risk factor for development of lung cancer 
4,5
. Additionally, 
lung cancer incidence has been also shown to be associated with the presence of emphysema 
on CT scan independently of the degree of airway obstruction or smoking history 
6,7
. These 
findings might implicate a pathophysiological link between COPD and lung cancer beyond 
that of smoking 
8
.  
COPD, however, is a heterogeneous disease where the different phenotypes may overlap, and 
it is unclear whether COPD patients with predominant airway inflammation have a similar 
increased lung cancer risk. Earlier studies have found an association between systemic 
inflammation and both frequent exacerbations and a higher mortality in COPD patients 
9
. 
Nevertheless, a potential link between systemic inflammation and lung cancer development 
has not been sufficiently explored. Research on this topic may be useful both for finding 
cancer biomarkers for detection of early cancer, as well as gaining a better understanding of 
mechanisms by which lung tissue in some COPD patients undergo malignant transformation.  
Our study aimed to evaluate several different COPD phenotypes and characteristics as risk 
factors for the development of lung cancer, combining clinical data and systemic 
inflammatory markers from a large COPD cohort study with longitudinal follow up, merged 
with data from the Norwegian cancer registry. 
Materials and methods 
Study population 
433 subjects with COPD and 279 healthy controls, all between 40 and 76 years old, were 
recruited to the Bergen COPD Cohort Study between 2006 and 2009 
10
. Both COPD patients 
and controls had a smoking history of more than 10 pack-years. All COPD patients had a 
clinical diagnosis of COPD, a post-bronchodilation test with FEV1/FVC-ratio < 0.7, and FEV1 
< 80 % of predicted value. Exclusion criteria were known cancer within 5 years prior to entry, 
asthma or lung diseases other than COPD, active inflammatory disorders, and COPD 
exacerbations 4 weeks prior of inclusion, this latter category could be included later. The 
Regional Committee for Medical and Health Research Ethics, region west approved the study 
(REK-Vest, case number 2014/2153). Informed written consent was obtained from all 
participants. 
Data collection 
All subjects were evaluated by a study physician at inclusion, including a clinical interview 
regarding respiratory symptoms, smoking history, comorbidities and medication use. 
Comorbidities were pooled to calculate Charlson Comorbidity Score (CCS). All patients 
performed spirometry, before and after bronchodilation with 0.4 mg salbutamol. COPD 
patients were categorized according to 2007 Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidelines. The diagnosis of lung cancer was obtained from the Norwegian 
Cancer Registry, where registration is mandatory by law, with near 100 % coverage among 
both healthy controls and patients (see also supplementary materials) 
11
. Body composition 
was evaluated with bioelectrical impedance measurements. Cachexia was defined as a fat free 
mass index (FFMI) less than 17 kg/m
2
 or 14 kg/m
2
 in men and women, respectively 
12
, which 
corresponds to the lower 95% confidence limit in a normal population 
13
. Obesity was defined 
as a fat mass index (FMI) of more than 9.3 kg/m
2
 in men or more than 13.5 kg/m
2
 in women 
13
. Emphysema was assessed by computer tomography (CT) of the lungs, defined as having 
more than 10% of emphysematous lung tissue, specified as tissue density of less than -950 
HU. Chronic bronchitis was defined as having cough with phlegm for more than three months 
the year before inclusion. 
Laboratory measurements 
Peripheral blood sampling was performed as previously described 
10
. The analysis of the 44 
inflammatory markers was performed with enzyme immunoassays (EIAs) and magnetic bead 
multiplex assays (see supplementary files for details).  
Statistical methods 
The baseline comparison between the study populations (COPD patients vs controls, and 
cancer vs non-cancer subjects), was done using non-parametric tests (Wilcoxon rank-sum for 
continuous and χ²-test for categorical variables).  
A cox-regression model was fitted to evaluate risk factors of lung cancer in COPD patients vs 
smoking controls. Age, sex, smoking status, pack-years smoked, and body composition were 
adjustment factors. Similarly, for the evaluation of risk factors for lung cancer in COPD 
patients, a cox-regression model was fitted with adjustment using the same variables as 
described above.  In addition, the COPD characteristics emphysema, chronic bronchitis, 2 or 
more exacerbations last year before inclusion, and the use of inhalation medication was added 
to the model one at a time, and kept in the model if the p-value was below 0.05. 
The 44 biomarkers were to different degrees correlated, and for the statistical evaluation the 
markers were added one at a time to the model above. Due to multiple testing of biomarkers, a 
Bonferroni adjusted p-value below 0.05/45=0.0011 was demanded for statistical significance.  
The combined analysis of the variety of systemic inflammation between subjects was 
performed using a principal component analysis (PCA). PCA is a data reduction method that 
extracts and transforms the variance from multiple inter-correlated biomarkers into a smaller 
number of independent variables/components
14
. Principal components with eigenvalues above 
1 (average) were retained for analysis in the cox-regression model. The first four components, 
located above the breaking point of the scree-plot, all with eigenvalues above 2, were also 
visualized using scatterplots and correlation diagrams.  
Results 
The baseline characteristics of the study population are presented in Table 1. COPD patients 
were older, had different smoking habits and experienced cachexia and obesity more 
frequently than smokers without COPD. Thirty-one subjects had a diagnosis of lung cancer 
during follow up of which 28 where in the COPD group. The time between study inclusion 
and diagnosis of lung cancer varied between 48 days and 8.6 years. 





COPD                                                      
(n=433) p-Value* 
Age, mean (SD) 58.0 (10.0) 63.5 (6.9) <0.01 
Sex, No (%) 
     Female 128 (45.9) 175 (40.4) 0.15 
  Male 151 (54.1) 258 (59.6) 
 Smoking status, No (%) 
     Ex 103 (36.9) 243 (56.1) <0.01 
  Current 176 (63.1) 190 (43.9) 
 Packyears, mean (SD) 32.1 (21.5) 40.4 (22.7) <0.01 
Body composition, No (%) 
     Normal 248 (88.9) 242 (55.9) <0.01 
  Cachectic 11 (3.9) 123 (28.4) 
   Obese 20 (7.2) 68 (15.7) 
 
Charlson Comorbidity Score, No (%) 
     0 197 (70.6) 0 <0.01 
  1 61 (21.9) 250 (57.7) 
   2 16 (5.7) 102 (23.6) 
   3 5 (1.8) 51 (11.8) 
   4+ 0 30 (6.9) 
 Lung cancer, No (%) 3 (1.1) 28 (6.5) <0.01 
*χ² or Wilcoxon rank-sum test 
    
    
Lung cancer histology 
The different histology patterns are shown in Figure 1. Non-small cell lung carcinomas were 
dominant, with only one case of small-cell lung carcinoma.  
 
Figure 1 




Comparison between COPD patients and controls 
Table 2 shows unadjusted and adjusted hazard ratios in the combined COPD and control 
groups. COPD patients had a significantly higher risk of developing lung cancer during 
follow-up with a HR 5.0 (95% CI 1.5-17.1, p=0.01) after multivariable adjustment. Smoking 
status at inclusion or pack-years smoked were not associated with lung cancer. 




 Variables HR 95 % CI p-value HR 95 % CI p-value 
 Age per 10 year increase 1.97 (1.24 to 3.13) 0.004 1.82 (1.04 to 3.20) 0.04 
 Sex 
   
  
     Female 1 
  
1 
     Male 1.08 (0.53 to 2.20) 0.84 0.86 (0.41 to 1.82) 0.69 
 Smoking status 
   
  
     Ex 1 
  
1 
     Current 0.57 (0.28 to 1.18) 0.13 1.18 (0.55 to 2.57) 0.67 
 Packyears per 10 units increase 1.12 (0.99 to 1.25) 0.06 1.03 (0.90 to 1.18) 0.68 
 Body composition* 
   
  
     Normal 1 
  
1 
     Cachectic 0.92 (0.31 to 2.72) 0.88 0.48 (0.15 to 1.48) 0.20 
   Obese 2.91 (1.31 to 6.48) 0.009 2.13 0.92 to 4.92) 0.08 
 Patient category* 
   
  
     Control 1 
  
1 
     COPD-patient 6.33 (1.92 to 20.8) 0.002 4.98 (1.45 to 17.1) 0.01 
 *All controls and patients were current or former smokers 
      
Lung cancer risk related to COPD characteristics 
Figure 2 shows the accumulated risk for developing lung cancer in COPD patients with and 
without CT-defined emphysema.  
 
Figure 2 
Incidence of lung cancer in patients with and without emphysema during follow up. 
 
 
Table 3 shows the hazard ratios of the association of different COPD characteristics with lung 
cancer development. Factors associated with a higher lung cancer risk after multivariable 
adjustments were the presence of emphysema and/or obesity, whereas the use of inhaled 
corticosteroids (ICS) was associated with a lower risk (Table 3). Use of tiotropium was 
associated with a higher risk of lung cancer in the unadjusted model, but not after 
multivariable adjustment. When stratifying on gender, obesity only indicated a higher risk in 
males (HR 4.76; 1.4-16.0, p=0.01), but not in females (HR 1.34; 0.2-8.0, p=0.75). Similarly, 
the use of ICS indicated a lower risk in patients without emphysema (HR 0.13; 0.02-0.79, 
p=0.03), than in patients where emphysema was present (HR 0.47; 0.15-1.50, p=0.20). 
 




Variables HR 95 % CI p-value HR 95 % CI 
Age per 10 year increase 1.76 (0.98 to 3.16) 0.06 1.77 (0.88 to 3.55) 
Sex 
   
  
   Female 1 
  
1 
   Male 0.93 (0.44 to 1.97) 0.86 0.61 (0.27 to 1.39) 
Smoking status 
   
  
   Ex 1 
  
1 
   Current 0.69 (0.32 to 1.49) 0.33 1.41 (0.57 to 3.48) 
Packyears per 10 units increase 1.05 (0.92 to 1.21) 0.45 0.99 (0.85 to 1.17) 
Body composition 
   
  
   Normal 1 
  
1 
   Cachectic 0.58 (0.19 to 1.72) 0.32 0.32 (0.09 to 1.18) 
  Obese 1.99 0.85 to 4.66) 0.11 3.25 (1.25 to 8.45) 
Emphysema 
   
  
   No 1 
  
1 
   Yes 2.74 (1.19 to 6.31) 0.02 4.35 (1.74 to 10.8) 
Use of inhaled steroids 
   
  
   No 1 
  
1 
   Yes 0.74 (0.35 to 1.58) 0.44 0.40 (0.17 to 0.93) 
GOLD-status (2007)* 
   
  
   II 1 
  
  
   III 1.08 (0.50 to 2.34) 0.84   
   IV 0.78 (0.18 to 3.46) 0.75   
 Use of tiotropium* 
   
  
   No 1 
  
  
   Yes 2.20 (1.05 to 4.63) 0.04   
 Use of long-acting β2-agonists* 
   
  
   No 1 
  
  
   Yes 0.78 (0.40 to 1.97) 0.78   
 Exacerbations 12 months before inclusion* 
  
  
   0-1 1 
  
  
   2+ 0.62 (0.19 to 2.05) 0.43   
 Chronic bronchitis* 
   
  
    No 1 
  
  
   Yes 1.21 (0.58 to 2.54) 0.61   
 Charlson Comorbidity Score* 
   
  
   1 1 
  
  
   2 0.83 (0.30 to 2.27) 0.71   
   3 2.29 (0.89 to 5.91) 0.09   
   4+ 1.44 (0.33 to 6.33)     
 *p>0.05 in multivariable analysis 
      
Biomarkers related to the development of lung cancer 
Table 4a shows non-parametric analysis of 44 systemic biomarkers measured at study 
inclusion. Of the 44 markers, interleukin-6 (IL-6; p=0.01) and interferon gamma-induced 










 non-cancer lung cancer p-value* 
Hemoglobin 14.53 14.19 0.12 
Leucocytes 8.13 7.63 0.42 
Granulocytes 5.57 5.12 0.46 
Eosinophils 2.54 2.57 0.95 
Platelet count 293.89 279.48 0.30 
Activin-A 0.32 0.33 0.37 
ALCAM 73.94 71.87 0.67 
Basic FGF 63.91 60.48 0.34 
CD-163 315.46 293.59 0.75 
CRP 8.50 5.08 0.22 
s-Creatinine 67.84 67.36 0.69 
CXCL-16 783.28 836.98 0.31 
Eotaxin 92.33 87.10 0.17 
s-Ferritin 136.29 143.07 0.65 
G-CSF 216.23 217.29 0.18 
GDF-15 0.98 0.92 0.52 
GM-CSF 98.45 56.44 0.39 
IFN-γ 330.46 271.55 0.31 
IL-1 0.96 0.55 0.59 
IL-2 39.41 12.73 0.60 
IL-4 15.06 15.86 0.39 
IL-5 13.12 12.43 0.97 
IL-6 2.96 1.13 0.01 
IL-7 30.60 31.92 0.47 
IL-8 33.65 35.35 0.39 
IL-9 38.32 34.29 0.37 
IL-10 80.53 45.93 0.87 
IL-12 259.89 77.80 0.82 
IL-13 163.04 43.66 0.48 
IL-17 93.26 96.41 0.37 
IP-10 768.84 1057.31 0.02 
MBL 828.55 525.29 0.10 
MCP-1 63.57 59.30 0.85 
MCP-4 90.59 85.02 0.62 
MIF 24.79 21.41 0.50 
MIP-1α 8.83 8.17 0.83 
MIP-1β 53.88 52.87 0.90 
NAP-2 170.89 165.91 0.41 
NGAL 75.69 68.55 0.30 
OPG 5770.63 6247.31 0.29 
PDGF-BB 1128.54 1093.75 0.81 
TNF-R1 736.45 752.24 0.78 
TNF-α 1.80 1.68 0.59 
VEGF 48.20 46.19 0.66 
 
Evaluation of biomarkers one at a time in the adjusted cox-regression analysis (Table 4b) 
showed that only IP-10 is significantly associated with lung cancer (HR 1.80; 1.32-2.45, 
p<0.001, per 1 SD increase), after multivariate adjustment. Higher levels of IP10 indicated a 
higher cancer risk in patients with emphysema (HR 2.05; 1.45-2.90, p<0.01), than in non-
emphysema patients (HR 0.95; 0.38-2.40, p=0.92). 
Table 4b Multivariate cox-regression of biomarkers and principal 
components in non-cancer vs cancer in COPD-patients 
    Biomarker HR * 95 % CI p-value
#
 
Hemoglobin 0.78 (0.52-1.17) 0.23 
Leucocytes 0.80 (0.51-1.25) 0.33 
Granulocytes 0.77 (0.49-1.22) 0.27 
Eosinophils 0.89 (0.55-1.43) 0.64 
Platelet count 0.88 (0.56-1.38) 0.58 
Activin-A 0.87 (0.57-1.35) 0.54 
ALCAM 0.73 (0.41-1.33) 0.31 
Basic FGF 1.04 (0.70-1.54) 0.84 
CD-163 0.82 (0.46-1.44) 0.48 
CRP 0.66 (0.35-1.24) 0.20 
s-Creatinine 0.88 (0.56-1.38) 0.58 
CXCL-16 1.24 (0.81-1.89) 0.32 
Eotaxin 1.01 (0.65-1.57) 0.96 
s-Ferritin 1.09 (0.81-1.46) 0.58 
G-CSF 0.98 (0.62-1.55) 0.94 
GDF-15 0.99 (0.59-1.65) 0.98 
GM-CSF 0.56 (0.13-2.34) 0.43 
IFN-γ 0.89 (0.45-1.76) 0.74 
IL-1 0.60 (0.29-1.24) 0.17 
IL-2 0.72 (0.12-4.24) 0.71 
IL-4 1.09 (0.76-1.57) 0.64 
IL-5 1.03 (0.70-1.52) 0.89 
IL-6 0.25 (0.02-3.61) 0.31 
IL-7 1.08 (0.82-1.43) 0.59 
IL-8 1.16 (0.80-1.68) 0.44 
IL-9 0.93 (0.57-1.51) 0.77 
IL-10 0.91 (0.50-1.66) 0.76 
IL-12 0.16 (0.00-75.8) 0.56 
IL-13 0.46 (0.07-3.06) 0.42 
IL-17 1.05 (0.71-1.57) 0.80 
IP-10 1.80 (1.32-2.45) <0.001 
MBL 0.68 (0.38-1.23) 0.20 
MCP-1 0.97 (0.64-1.46) 0.87 
MCP-4 0.82 (0.82-1.28) 0.37 
MIF 0.78 (0.46-1.32) 0.35 
MIP-1α 0.99 (0.48-2.02) 0.98 
MIP-1β 0.92 (0.60-1.40) 0.68 
NAP-2 0.87 (0.61-1.26) 0.47 
NGAL 0.70 (0.47-1.11) 0.13 
OPG 1.07 (0.72-1.60) 0.74 
PDGF-BB 0.96 (0.63-1.48) 0.87 
TNF-R1 0.92 (0.61-1.38) 0.69 
TNF-α 1.04 (0.68-1.58) 0.84 
VEGF 1.00 (0.67-1.51) 0.97 
Principal components HR 95 % CI p-value 
PC1 1.00 (0.89-1.14) 0.94 
PC2 0.96 (0.78-1.18) 0.69 
PC3 0.87 (0.66-1.15) 0.34 
PC4 0.74 (0.54-1.01) 0.06 
PC5 1.26 (0.90-1.76) 0.17 
PC6 0.71 (0.50-1.00) 0.05 
PC7 0.89 (0.60-1.31) 0.54 
PC8 1.04 (0.69-1.56) 0.85 
PC9 1.17 (0.79-1.73) 0.44 
PC10 0.83 (0.52-1.32) 0.43 
PC11 0.59 (0.38-0.92) 0.02 
* per 1 SD increase  
    
The combined effect of the 44 biomarkers was evaluated by principal component analysis 
using components 1-11 with eigenvalues above 1, representing 71% of the cumulative 
variance of the biomarkers. The values of the different eigenvectors, and the markers included 
in each principal component, are shown in the supplementary material. The principal 
components 1-11 were also analysed using the cox-regression model described above, but no 
significant statistical difference was observed between lung cancer and non-cancer patients 
(Table 4b). The distribution of component 1-4 of the principal component analysis of the 44 
biomarkers in lung cancer vs non-cancer patients is shown in Figure 3. 
 
Figure 3 
Systemic inflammation in non-cancer vs lung cancer patients represented by principal 
components 1-4 of the systemic inflammatory markers, measured at study inclusion. 
Scatterplots of components 1 vs 2 and 3vs 4 shows no visually nor statistically significant 
difference between the groups. 
 
Figure 4 shows the correlations between the different COPD characteristics and biomarkers of 
systemic inflammation represented by the principal components 1-4. There was a higher 
degree of correlation between the components and the COPD characteristics of frequent 
exacerbations and chronic bronchitis, than with lung cancer or emphysema.  
 
Figure 4 
Correlation diagram showing the relations between COPD characteristics and systemic 
inflammation at study inclusion represented by principal components 1-4. Thicker line 
indicates larger degree of correlation, solid line indicates positive correlation, dashed line 




The results of this study showed that both current and ex-smoking COPD patients, 
irrespective of packyears smoked, had an increased risk of lung cancer. Further, the presence 
of emphysema and obesity was associated with an increased lung cancer risk, whereas the use 
of ICS was associated with a reduced risk. Among 44 systemic biomarkers, only IP-10 was 
significantly associated with the development of lung cancer after multivariable adjustment. 
The study did not demonstrate any clear association between lung cancer and the COPD 
characteristics of chronic bronchitis, frequent exacerbations, or markers of systemic 
inflammation beside IP-10.  
A diagnosis of COPD, and especially with the presence of emphysema, was a risk factor for 
developing lung cancer in our study. Current smoking or a high pack-year count did not 
increase the risk, suggesting the persistence of lung damage even after quitting smoking, or 
after a moderate amount of smoking. These findings are in accordance with earlier studies 
which have demonstrated a relationship between a diagnosis of COPD and lung cancer or 
death of lung cancer irrespective of the amount of smoking 
3-5,15
. Subsequent studies have 
further evaluated this relationship, where the presence of emphysema in COPD patients was 
associated with both a diagnosis of lung cancer, but also death due to lung cancer as well as 
non-pulmonary cancer 
6,7,16
. The co-existence of emphysema and lung cancer may obviously 
be ascribed to their common risk factor of noxious airway exposure. However, a common 
pathophysiology of these two conditions is nevertheless more difficult to explain, with 
apoptosis and protein degrading as main characteristics of emphysema as opposed to the 
excessive cell growth in cancer. Possible mechanistic explanations of cancer development 
include accelerated proliferation of epithelial cells resistant to apoptosis, dysfunction of 
proteinase-regulation, and increased generation of pro-inflammatory cells, cytokines and 
reactive oxygen species 
8,17
. 
There is extensive research data linking systemic inflammation and cancer in general 
18
. In 
lung cancer, this relationship is less well described, but several studies have demonstrated 
elevated inflammatory mediators in patients with established lung cancer 
19-22
. An important 
study question to address was whether indices of systemic inflammation could predict lung 
cancer in COPD patients. Interrelated phenotypic attributes such as chronic bronchitis and 
frequent exacerbations were also associated with increased systemic inflammation, but none 
of them had a significant association with the development of lung cancer. We evaluated 
inflammatory biomarkers both individually as well as combined with principal component 
analysis, with mostly negative findings regarding any predictive value of lung cancer. 
However, the principal component analysis indicated a closer association between 
inflammatory markers and patients with mainly chronic bronchitis and exacerbations, rather 
than in patients with emphysema or with high lung cancer risk, suggesting the existence of 
different pathophysiological/immunological pathways underlying the different COPD 
phenotypes.  
Among 44 serum/plasma biomarkers, only high levels of IP-10 were associated with 
increased lung cancer risk. IP-10 (CXCL-10) is induced by IFNγ, and is frequently used as a 
marker of viral infection 
23,24
. Its functions include induction of chemotaxis, regulation of cell 
growth/apoptosis and angiogenesis. Spaks et al found elevated serum IP-10 in lung cancer 
patients 
25
, and high expression is also seen in other cancer types. The role of IP-10 in cancer 
may depend on its receptor; it may be involved in tumor growth inhibition through angiostatic 
or immunogenic actions or in direct tumor growth stimulation. The role of IP-10 in either 
COPD or lung cancer is yet unclear, and thus it should be further investigated.  
The association between the use of ICS and a lower risk of lung cancer is in accordance with 
prior observational studies 
26-28
, and may indicate a protective effect of ICS. The above 
mentioned link between inflammation and cancer may be modified by ICS, and the potential 
protective mechanisms of ICS may include reduced secretion of carcinogenic cytokines or 
growth-factors in the lungs, as well as inhibition of proto-oncogene expression 
29,30
. On the 
other hand, a similar effect has not been found in randomized controlled studies 
31,32
, and the 
observed effect of ICS may be due to a protopathic bias. However randomized controlled 
trials are neither designed nor have had a sufficient follow up time to evaluate lung cancer 
risk, thus a potential preventive effect of ICS is still possible although unproven 
33,34
.  
A major finding in the present study was an independent association between obesity and lung 
cancer development in COPD patients, primarily reflecting an association in males. Obesity is 
described as a risk factor of several variants of cancer 
35
, however, regarding lung cancer, 
several prior studies report opposing findings where some have reported a protective effect of 
high BMI 
36,37
. This is, nevertheless, a complex matter to study, where several confounding 
factors such as smoking habits, genetics and dietary issues may affect the findings in the 
different study populations 
38,39
. Recently, a large study where 23,732 incident lung cancer 
cases were identified suggested that central obesity, particularly concurrent with low BMI, 
could help identify high-risk populations for lung cancer 
40
, and future studies in COPD 
patients in relation to cancer development should also include fat distribution as a parameter.  
There is an ongoing international debate on lung cancer screening 
41
. Early detection of lung 
cancer using low-dose computer tomography is probably the most important measure in 
reducing mortality 
42
. Most screening protocols consider smoking and aging as the most 
important risk factors, though some recent studies promotes the inclusion of additional 
parameters to narrow the screening population 
43-45
. Screening appears to be more 
advantageous in case of emphysema phenotype of COPD, but less in case of COPD with 
chronic bronchitis or other forms of chronic inflammation. The results of our study support 
narrowing the screening population based on presence of airflow limitation as well as 
indications of emphysema.  
The strengths of our study were its prospective design with outcomes from a mandatory 
national registry, and the availability of detailed information on a large number of patients 
allowing adjustment of multiple variables.  
Some limitations should be mentioned. First, the patients were not randomized, and therefore 
data interpretation regarding causality is difficult. Second, the serum/plasma inflammatory 
markers were measured only at entry, and thus it is uncertain to what extent this is 
representative of lung inflammation or whether the degree of systemic inflammation in the 
subjects is altered during follow-up. Third, the study population represents an outpatient clinic 
population, with exclusion of GOLD class 1 patients and, thus the results may not be 
applicable to a COPD population with early stage disease. Finally, there was no systematic 
screening of lung cancer. Thus, although the Norwegian Cancer Registry has a high degree of 
completeness, we cannot exclude cases of non-reported lung cancer among patients or 
controls.  
The present study clearly underscores the necessity of looking at COPD as a heterogeneous 
disease, where the different phenotypes not only require different diagnostics and treatment, 
but where they also incorporate different risks of adverse events such as lung cancer 
development. The idea of using serum/plasma biomarkers in early lung cancer screening may 
presently seem challenging, but an increasingly easier access to large multiplex bioassays and 
a better understanding of the pathophysiologic mechanisms behind the COPD phenotypes 
might change this view in the near future.   
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